A strongly transdominant mutation in the human immunodeficiency virus type 1 gag gene defines an achilles heel in the virus life cycle

Journal of Virology

Volumn 83, Issue 17, 2009, Pages 8536-8543

  Lee, Sook Kyung ^a   Harris, Janera ^a   Swanstrom, Ronald ^a,b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; CAPSID PROTEIN; GAG PROTEIN; HYBRID PROTEIN; ISOLEUCINE; MATRIX PROTEIN; OLIGOMER; VIRUS DNA; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN; P16 PROTEASE, HUMAN IMMUNODEFICIENCY VIRUS 1; P17 PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS TYPE 1; PROTEINASE;

ARTICLE; CONTROLLED STUDY; DNA SYNTHESIS; EMBRYO; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; LIFE CYCLE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN DOMAIN; PROTEIN PROCESSING; PROTEIN TARGETING; REVERSE TRANSCRIPTION; VIRION; VIRUS ASSEMBLY; VIRUS GENE; VIRUS INFECTIVITY; VIRUS MUTATION; WILD TYPE; AMINO ACID SUBSTITUTION; ANIMAL; GENETICS; METABOLISM; MISSENSE MUTATION; PHYSIOLOGY; PROTEIN MULTIMERIZATION; SITE DIRECTED MUTAGENESIS; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS 1; MIRIDAE;

AMINO ACID SUBSTITUTION; ANIMALS; GAG GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; HIV ANTIGENS; HIV CORE PROTEIN P24; HIV PROTEASE; HIV-1; HUMANS; MUTAGENESIS, SITE-DIRECTED; MUTATION, MISSENSE; PROTEIN MULTIMERIZATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; VIRUS ASSEMBLY; VIRUS REPLICATION;

EID: 69249216636     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.00317-09     Document Type: Article

References (49)

1. Bahner, I., T. Sumiyoshi, M. Kagoda, R. Swartout, D. Peterson, K. Pepper, F. Dorey, J. Reiser, and D. B. Kohn. 2007. Lentiviral vector transduction of a dominant-negative Rev gene into human CD34+ hematopoietic progenitor cells potently inhibits human immunodeficiency virus-1 replication. Mol. Ther. 15:76-85.
2. Bahner, I., C. Zhou, X. J. Yu, Q. L. Hao, J. C. Guatelli, and D. B. Kohn. 1993. Comparison of trans-dominant inhibitory mutant human immunodeficiency virus type 1 genes expressed by retroviral vectors in human T lymphocytes. J. Virol. 67:3199-3207.
3. Bandyopadhyay, P. K., S. Watanabe, and H. M. Temin. 1984. Recombination of transfected DNAs in vertebrate cells in culture. Proc. Natl. Acad. Sci. USA 81:3476-3480.
4. Bauer, G., P. Valdez, K. Kearns, I. Bahner, S. F. Wen, J. A. Zaia, and D. B. Kohn. 1997. Inhibition of human immunodeficiency virus-1 (HIV-1) replication after transduction of granulocyte colony-stimulating factor-mobilized CD34+ cells from HIV-1-infected donors using retroviral vectors containing anti-HIV-1 genes. Blood 89:2259-2267. (Pubitemid 27143270)
5. Bevec, D., M. Dobrovnik, J. Hauber, and E. Bohnlein. 1992. Inhibition of human immunodeficiency virus type 1 replication in human T cells by retroviral- mediated gene transfer of a dominant-negative Rev trans-activator. Proc. Natl. Acad. Sci. USA 89:9870-9874.
6. Bjorndal, A., H. Deng, M. Jansson, J. R. Fiore, C. Colognesi, A. Karlsson, J. Albert, G. Scarlatti, D. R. Littman, and E. M. Fenyo. 1997. Coreceptor usage of primary human immunodeficiency virus type 1 isolates varies according to biological phenotype. J. Virol. 71:7478-7487. (Pubitemid 27391688)
7. Briggs, J. A., M. N. Simon, I. Gross, H. G. Krausslich, S. D. Fuller, V. M. Vogt, and M. C. Johnson. 2004. The stoichiometry of Gag protein in HIV-1. Nat. Struct. Mol. Biol. 11:672-675.
8. Cairns, T. M., and R. C. Craven. 2001. Viral DNA synthesis defects in assembly-competent Rous sarcoma virus CA mutants. J. Virol. 75:242-250.
9. Cordelier, P., E. Van Bockstaele, S. A. Calarota, and D. S. Strayer. 2003. Inhibiting AIDS in the central nervous system: gene delivery to protect neurons from HIV. Mol. Ther. 7:801-810.
10. Coren, L. V., J. A. Thomas, E. Chertova, R. C. Sowder II, T. D. Gagliardi, R. J. Gorelick, and D. E. Ott. 2007. Mutational analysis of the C-terminal gag cleavage sites in human immunodeficiency virus type 1. J. Virol. 81:10047-10054.
11. Crowder, S., and K. Kirkegaard. 2005. Trans-dominant inhibition of RNA viral replication can slow growth of drug-resistant viruses. Nat. Genet. 37:701-709.
12. Douek, D. C., J. M. Brenchley, M. R. Betts, D. R. Ambrozak, B. J. Hill, Y. Okamoto, J. P. Casazza, J. Kuruppu, K. Kunstman, S. Wolinsky, Z. Grossman, M. Dybul, A. Oxenius, D. A. Price, M. Connors, and R. A. Koup. 2002. HIV preferentially infects HIV-specific CD4+ T cells. Nature 417:95-98. (Pubitemid 34498823)
13. DuBridge, R. B., P. Tang, H. C. Hsia, P. M. Leong, J. H. Miller, and M. P. Calos. 1987. Analysis of mutation in human cells by using an Epstein-Barr virus shuttle system. Mol. Cell. Biol. 7:379-387.
14. Forshey, B. M., U. von Schwedler, W. I. Sundquist, and C. Aiken. 2002. Formation of a human immunodeficiency virus type 1 core of optimal stability is crucial for viral replication. J. Virol. 76:5667-5677. (Pubitemid 34517917)
15. Furuta, R. A., R. Shimano, T. Ogasawara, R. Inubushi, K. Amano, H. Akari, M. Hatanaka, M. Kawamura, and A. Adachi. 1997. HIV-1 capsid mutants inhibit the replication of wild-type virus at both early and late infection phases. FEBS Lett. 415:231-234.
16. Gottlinger, H. G., J. G. Sodroski, and W. A. Haseltine. 1989. Role of capsid precursor processing and myristoylation in morphogenesis and infectivity of human immunodeficiency virus type 1. Proc. Natl. Acad. Sci. USA 86:5781-5785.
17. Green, M., M. Ishino, and P. M. Loewenstein. 1989. Mutational analysis of HIV-1 Tat minimal domain peptides: identification of trans-dominant mutants that suppress HIV-LTR-driven gene expression. Cell 58:215-223. (Pubitemid 19180093)
18. Henderson, L. E., M. A. Bowers, R. C. Sowder II, S. A. Serabyn, D. G. Johnson, J. W. Bess, Jr., L. O. Arthur, D. K. Bryant, and C. Fenselau. 1992. Gag proteins of the highly replicative MN strain of human immunodeficiency virus type 1: posttranslational modifications, proteolytic processings, and complete amino acid sequences. J. Virol. 66:1856-1865.
19. Kaplan, A. H., J. A. Zack, M. Knigge, D. A. Paul, D. J. Kempf, D. W. Norbeck, and R. Swanstrom. 1993. Partial inhibition of the human immunodeficiency virus type 1 protease results in aberrant virus assembly and the formation of noninfectious particles. J. Virol. 67:4050-4055.
20. Kawada, S., T. Goto, H. Haraguchi, A. Ono, and Y. Morikawa. 2008. Dominant negative inhibition of human immunodeficiency virus particle production by the nonmyristoylated form of gag. J. Virol. 82:4384-4399. (Pubitemid 351563675)
21. Kelly, B. N., B. R. Howard, H. Wang, H. Robinson, W. I. Sundquist, and C. P. Hill. 2006. Implications for viral capsid assembly from crystal structures of HIV-1 Gag(1-278) and CA(N)(133-278). Biochemistry 45:11257-11266.
22. Kelly, B. N., S. Kyere, I. Kinde, C. Tang, B. R. Howard, H. Robinson, W. I. Sundquist, M. F. Summers, and C. P. Hill. 2007. Structure of the antiviral assembly inhibitor CAP-1 complex with the HIV-1 CA protein. J. Mol. Biol. 373:355-366.
23. Li, F., R. Goila-Gaur, K. Salzwedel, N. R. Kilgore, M. Reddick, C. Matallana, A. Castillo, D. Zoumplis, D. E. Martin, J. M. Orenstein, G. P. Allaway, E. O. Freed, and C. T. Wild. 2003. PA-457: a potent HIV inhibitor that disrupts core condensation by targeting a late step in Gag processing. Proc. Natl. Acad. Sci. USA 100:13555-13560.
24. Malim, M. H., S. Bohnlein, J. Hauber, and B. R. Cullen. 1989. Functional dissection of the HIV-1 Rev trans-activator - derivation of a trans-dominant repressor of Rev function. Cell 58:205-214.
25. Malim, M. H., W. W. Freimuth, J. Liu, T. J. Boyle, H. K. Lyerly, B. R. Cullen, and G. J. Nabel. 1992. Stable expression of transdominant Rev protein in human T cells inhibits human immunodeficiency virus replication. J. Exp. Med. 176:1197-1201.
26. Moore, M. D., W. Fu, F. Soheilian, K. Nagashima, R. G. Ptak, V. K. Pathak, and W. S. Hu. 2008. Suboptimal inhibition of protease activity in human immunodeficiency virus type 1: effects on virion morphogenesis and RNA maturation. Virology 379:152-160.
27. Morikawa, Y., S. Hinata, H. Tomoda, T. Goto, M. Nakai, C. Aizawa, H. Tanaka, and S. Omura. 1996. Complete inhibition of human immunodefi- ciency virus Gag myristoylation is necessary for inhibition of particle budding. J. Biol. Chem. 271:2868-2873.
28. Mortuza, G. B., L. F. Haire, A. Stevens, S. J. Smerdon, J. P. Stoye, and I. A. Taylor. 2004. High-resolution structure of a retroviral capsid hexameric amino-terminal domain. Nature 431:481-485.
29. Pettit, S. C., G. J. Henderson, C. A. Schiffer, and R. Swanstrom. 2002. Replacement of the P1 amino acid of human immunodeficiency virus type 1 Gag processing sites can inhibit or enhance the rate of cleavage by the viral protease. J. Virol. 76:10226-10233.
30. Pettit, S. C., J. Simsic, D. D. Loeb, L. Everitt, C. A. Hutchison III, and R. Swanstrom. 1991. Analysis of retroviral protease cleavage sites reveals two types of cleavage sites and the structural requirements of the P1 amino acid. J. Biol. Chem. 266:14539-14547.
31. Plavec, I., M. Agarwal, K. E. Ho, M. Pineda, J. Auten, J. Baker, H. Matsuzaki, S. Escaich, M. Bonyhadi, and E. Bohnlein. 1997. High transdominant RevM10 protein levels are required to inhibit HIV-1 replication in cell lines and primary T cells: implication for gene therapy of AIDS. Gene Ther. 4:128-139. (Pubitemid 27096137)
32. Podsakoff, G. M., B. C. Engel, D. A. Carbonaro, C. Choi, E. M. Smogorzewska, G. Bauer, D. Selander, S. Csik, K. Wilson, M. R. Betts, R. A. Koup, G. J. Nabel, K. Bishop, S. King, M. Schmidt, C. von Kalle, J. A. Church, and D. B. Kohn. 2005. Selective survival of peripheral blood lymphocytes in children with HIV-1 following delivery of an anti-HIV gene to bone marrow CD34(+) cells. Mol. Ther. 12:77-86.
33. Rulli, S. J., Jr., D. Muriaux, K. Nagashima, J. Mirro, M. Oshima, J. G. Baumann, and A. Rein. 2006. Mutant murine leukemia virus Gag proteins lacking proline at the N-terminus of the capsid domain block infectivity in virions containing wild-type Gag. Virology 347:364-371.
34. Sticht, J., M. Humbert, S. Findlow, J. Bodem, B. Muller, U. Dietrich, J. Werner, and H. G. Krausslich. 2005. A peptide inhibitor of HIV-1 assembly in vitro. Nat. Struct. Mol. Biol. 12:671-677.
35. Strayer, D. S., F. Branco, J. Landre, M. BouHamdan, F. Shaheen, and R. J. Pomerantz. 2002. Combination genetic therapy to inhibit HIV-1. Mol. Ther. 5:33-41.
36. Swanstrom, R., and J. W. Wills. 1997. Synthesis, assembly, and processing of viral proteins, p. 263-334. In J. M. Coffin, S. H. Hughes, and H. E. Varmus (ed.), Retroviruses. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
37. Tang, C., E. Loeliger, I. Kinde, S. Kyere, K. Mayo, E. Barklis, Y. Sun, M. Huang, and M. F. Summers. 2003. Antiviral inhibition of the HIV-1 capsid protein. J. Mol. Biol. 327:1013-1020.
38. Tang, C., Y. Ndassa, and M. F. Summers. 2002. Structure of the N-terminal 283-residue fragment of the immature HIV-1 Gag polyprotein. Nat. Struct. Biol. 9:537-543.
39. Tang, S., T. Murakami, N. Cheng, A. C. Steven, E. O. Freed, and J. G. Levin. 2003. Human immunodeficiency virus type 1 N-terminal capsid mutants containing cores with abnormally high levels of capsid protein and virtually no reverse transcriptase. J. Virol. 77:12592-12602. (Pubitemid 37430655)
40. Ternois, F., J. Sticht, S. Duquerroy, H. G. Krausslich, and F. A. Rey. 2005. The HIV-1 capsid protein C-terminal domain in complex with a virus assembly inhibitor. Nat. Struct. Mol. Biol. 12:678-682.
41. Trono, D., M. B. Feinberg, and D. Baltimore. 1989. HIV-1 Gag mutants can dominantly interfere with the replication of the wild-type virus. Cell 59:113-120. (Pubitemid 19248563)
42. von Schwedler, U. K., T. L. Stemmler, V. Y. Klishko, S. Li, K. H. Albertine, D. R. Davis, and W. I. Sundquist. 1998. Proteolytic refolding of the HIV-1 capsid protein amino-terminus facilitates viral core assembly. EMBO J. 17:1555-1568.
43. von Schwedler, U. K., K. M. Stray, J. E. Garrus, and W. I. Sundquist. 2003. Functional surfaces of the human immunodeficiency virus type 1 capsid protein. J. Virol. 77:5439-5450. (Pubitemid 36460957)
44. Wei, X., J. M. Decker, H. Liu, Z. Zhang, R. B. Arani, J. M. Kilby, M. S. Saag, X. Wu, G. M. Shaw, and J. C. Kappes. 2002. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob. Agents Chemother. 46:1896-1905.
45. Wiegers, K., G. Rutter, H. Kottler, U. Tessmer, H. Hohenberg, and H. G. Krausslich. 1998. Sequential steps in human immunodeficiency virus particle maturation revealed by alterations of individual Gag polyprotein cleavage sites. J. Virol. 72:2846-2854. (Pubitemid 28175521)
46. Wilk, T., and S. D. Fuller. 1999. Towards the structure of the human immunodeficiency virus: divide and conquer. Curr. Opin. Struct. Biol. 9:231-243.
47. Zhou, J., C. H. Chen, and C. Aiken. 2006. Human immunodeficiency virus type 1 resistance to the small molecule maturation inhibitor 3-O-(3′,3′-dimethylsuccinyl)-betulinic acid is conferred by a variety of single amino acid substitutions at the CA-SP1 cleavage site in Gag. J. Virol. 80:12095-12101.
48. Zhou, J., L. Huang, D. L. Hachey, C. H. Chen, and C. Aiken. 2005. Inhibition of HIV-1 maturation via drug association with the viral Gag protein in immature HIV-1 particles. J. Biol. Chem. 280:42149-42155.
49. Zhou, J., X. Yuan, D. Dismuke, B. M. Forshey, C. Lundquist, K. H. Lee, C. Aiken, and C. H. Chen. 2004. Small-molecule inhibition of human immunodeficiency virus type 1 replication by specific targeting of the final step of virion maturation. J. Virol. 78:922-929. (Pubitemid 38067613)